JP2018526988A5 - - Google Patents

Info

Publication number

JP2018526988A5

JP2018526988A5 JP2018505684A JP2018505684A JP2018526988A5 JP 2018526988 A5 JP2018526988 A5 JP 2018526988A5 JP 2018505684 A JP2018505684 A JP 2018505684A JP 2018505684 A JP2018505684 A JP 2018505684A JP 2018526988 A5 JP2018526988 A5 JP 2018526988A5

Authority

JP

Japan

Prior art keywords

seq

light chain

heavy chain

antigen

nos

Prior art date

2016-08-02

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000012634 fragment Substances 0.000 claims description 88
• 239000000427 antigen Substances 0.000 claims description 65
• 102000036639 antigens Human genes 0.000 claims description 65
• 108091007433 antigens Proteins 0.000 claims description 65
• 239000008194 pharmaceutical composition Substances 0.000 claims description 13
• 101710104526 Beta-klotho Proteins 0.000 claims description 11
• 102100020683 Beta-klotho Human genes 0.000 claims description 11
• 150000001413 amino acids Chemical class 0.000 claims description 8
• 108020004707 nucleic acids Proteins 0.000 claims description 8
• 102000039446 nucleic acids Human genes 0.000 claims description 8
• 150000007523 nucleic acids Chemical class 0.000 claims description 8
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 6
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 6
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
• 208000030159 metabolic disease Diseases 0.000 claims description 5
• 208000032928 Dyslipidaemia Diseases 0.000 claims description 4
• 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
• 238000003556 assay Methods 0.000 claims description 4
• 208000002705 Glucose Intolerance Diseases 0.000 claims description 3
• 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 3
• 206010022489 Insulin Resistance Diseases 0.000 claims description 3
• 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
• 206010033645 Pancreatitis Diseases 0.000 claims description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
• 102000051661 human KLB Human genes 0.000 claims description 3
• 201000001421 hyperglycemia Diseases 0.000 claims description 3
• 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 3
• 201000008980 hyperinsulinism Diseases 0.000 claims description 3
• 201000001320 Atherosclerosis Diseases 0.000 claims description 2
• 206010019280 Heart failures Diseases 0.000 claims description 2
• 208000008589 Obesity Diseases 0.000 claims description 2
• 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 2
• 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 2
• 208000006011 Stroke Diseases 0.000 claims description 2
• 208000029078 coronary artery disease Diseases 0.000 claims description 2
• 239000003814 drug Substances 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 235000020824 obesity Nutrition 0.000 claims description 2
• 102000005962 receptors Human genes 0.000 claims description 2
• 108020003175 receptors Proteins 0.000 claims description 2
• 238000004448 titration Methods 0.000 claims description 2
• 125000003275 alpha amino acid group Chemical group 0.000 claims 4
• 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
• 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
• 238000000034 method Methods 0.000 description 11
• 229910052805 deuterium Inorganic materials 0.000 description 3
• 108090000765 processed proteins & peptides Proteins 0.000 description 3
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 201000009104 prediabetes syndrome Diseases 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
• 101001139095 Homo sapiens Beta-klotho Proteins 0.000 description 1
• 108010087468 NOV 002 Proteins 0.000 description 1
• 230000036528 appetite Effects 0.000 description 1
• 235000019789 appetite Nutrition 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• DRFILBXQKYDTFW-JIWRMXRASA-L disodium;2-[[(2r)-2-[[(4s)-4-amino-4-carboxybutanoyl]amino]-3-[[(2r)-2-[[(4s)-4-amino-4-carboxybutanoyl]amino]-3-(carboxylatomethylamino)-3-oxopropyl]disulfanyl]propanoyl]amino]acetate Chemical compound [Na+].[Na+].OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC([O-])=O)CSSC[C@@H](C(=O)NCC([O-])=O)NC(=O)CC[C@H](N)C(O)=O DRFILBXQKYDTFW-JIWRMXRASA-L 0.000 description 1
• 230000000694 effects Effects 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000012631 food intake Nutrition 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1